Patent Law Weblog
recent posts
- USPTO Moves to Protect Design Rights for Digital Innovations
- Judicial Conduct and Disability Committee Has Its Say, Denies Judge Newman’s Latest Request for Review
- PTAB Issues Judgment on Priority in CRISPR Interference
- Parties File Supplemental Priority Statements in CRISPR Interference
- Why the Alice Test is Stupid, Part V: The Goalposts Keep Moving
about
Category: Patent Profiles
-
By Christopher P. Singer — In a January 24, 2007 press release, EvoGenix Ltd announced that U.S. Patent No. 7,166,697, titled "V-like domain binding molecules" has been granted by the U.S. Patent Office. According to EvoGenix, the patent covers a protein technology termed "Evibodies®," which are similar to antibodies and are useful in…
-
By Christopher P. Singer — In a December 14, 2006 press release, Mirus Bio Corporation announced that U.S. Patent No. 7,148,205, titled "Intravascular Delivery of Non-Viral Nucleic Acid" has been granted by the U.S. Patent Office. According to Mirus Bio, the patent covers a technology for the administration of molecules that can induce RNA…
-
By Christopher P. Singer — In a November 27, 2006 press release Cytogen announced that U.S. Patent No. 7,135,457 issued for oral drug delivery agents that are random peptide compositions that bind to gastro-intestinal tract (GIT) transport receptors. These agents aid in the transport of active agents from the lumen of mammalian GIT…
-
By Christopher P. Singer — In a November 22, 2006 press release, Introgen Therapeutics, Inc. (INGN) announced that it has been awarded U.S. Patent No. 7,125,706, titled "An Improved Method for the Production and Purification of Adenoviral Vectors." This patent represents the third issued U.S. patent in Introgen’s adenoviral vector intellectual property portfolio. …
Patent Docs 